eazySNP System
New Innovative Molecular Technology Combination “LAMP + CRISPR” as CE-IVD
A Collaboration Leads to Molecularbiological Innovation
GARS-BAHNHOF, Germany, 29th of September 2026 — AmplexDiagnostics and Scope Biosciences are proud to introduce a groundbreaking solution in molecular diagnostics. In a new approach, “eazySNP” combines the highly specialized molecular technologies LAMP and CRISPR. By integrating these two methods, eazySNP enables the rapid and highly specific detection of genetic variants. This technological synergy was made possible through the scientific collaboration between AmplexDiagnostics and Scope Biosciences and represents a significant advancement in molecular SNP diagnostics, demonstrated by the successful introduction of the first CE-IVD-certified product based on this technology.
First product: eazySNP C. auris FKS1 S639 (CE-IVD)
With the first application of the eazySNP technology, AmplexDiagnostics targets one of the world's most significant multidrug-resistant yeast pathogens: Candidozyma auris. “eazySNP C. auris FKS1 S639” is the first CE-IVD-certified diagnostic test of its kind and enables the highly specific detection of clinically relevant mutations in the FKS1 gene associated with echinocandin resistance. As echinocandins currently represent the first-line treatment option for C. auris infections, the rapid identification of resistance-associated variants is of considerable clinical importance. The assay is performed directly from a yeast colony on the AmplexDiagnostics eazyMini platform and delivers results within just 45 minutes. The eazySNP technology therefore provides, for the first time, a rapid and targeted molecular solution for the detection of this important resistance marker.
For Scope Biosciences, the launch represents a strategic expansion from molecular diagnostics for plant health into human molecular diagnostics.
“This launch is an important milestone for Scope Biosciences: our CRISPR technology has moved from a versatile platform to a regulated product that addresses a concrete diagnostic need,” said Bas van der Baan, CEO of Scope Biosciences. “Together with AmplexDiagnostics, we have translated single-nucleotide precision into a practical assay for routine laboratories. It marks our entry into human diagnostics while we continue expanding our portfolio for plant health.”
About AmplexDiagnostics GmbH
Since 2002, AmplexDiagnostics (based in Gars-Bahnhof, Germany) has been providing precise and innovative solutions in molecular diagnostics. Using the ultra-fast LAMP-technology, the company so far developed many reliable and easy-to-use assays for the detection of infectious bacteria and fungi, with a focus on their resistance markers against antibiotics and antimycotics. Through its international scientific network and global distribution channels, the company has established itself as a key player in the field of molecular in vitro diagnostics. AmplexDiagnostics' continued growth is driven by its ability to respond rapidly to emerging diagnostic challenges and to translate them into practical solutions for hospitals and diagnostic laboratories. Learn more at www.eazyplex.com.
About Scope Biosciences B.V.
Scope Biosciences B.V. is a molecular-diagnostics company based in Wageningen, the Netherlands, and a spin-off from Wageningen University & Research. Its patented scopeDx® platform uses CRISPR-Cas to enable rapid and highly specific detection of genetic material, including single-nucleotide variants. Scope develops and commercializes diagnostics for plant health and works with partners to translate its technology into human-health applications. The eazySNP launch marks the first commercial human in vitro diagnostic product incorporating Scope’s CRISPR technology. Learn more at www.scopebio.com.
Outlook: The Future of “eazySNP” Technology
With the eazySNP technology platform, AmplexDiagnostics and Scope Biosciences are laying the foundation for a new generation of molecular diagnostic tests for the rapid detection of clinically relevant genetic variants.
Contact:
If you would like to learn more, please feel free to contact us!
Email: info@eazyplex.com
Phone: +49 8073 91693 – 50
Using a optimzed LAMP-primerset the target region of the gene of interest (carrying the position of SNP in a non-binding region between the FIP-and BIP-primer) is amplified.
Then with the help of a CRISPR RNA (crRNA), the type-III CRISPR-Cas protein complex detects the sequence of interest (SNP or insertion) with high specificity.
Upon recognition and binding, the type-III CRISPR-Cas complex produces cyclic oligoadenylate (cOA) from adenosine triphosphate (ATP) molecules. The generated cOA subsequently activates an RNase, an enzyme that cleaves a fluorescent reporter RNA. After cleavage of the fluorescent reporter, the resulting fluorescent signal can be measured.
